Precision Biosciences (DTIL) Equity Income (2021 - 2025)
Precision Biosciences (DTIL) reported Equity Income of -$2.9 million for Q4 2025, down 194.86% year-over-year from $3.0 million in Q4 2024, and down 384.94% quarter-over-quarter from -$591000.0 in Q3 2025.
Precision Biosciences (DTIL) Equity Income (2021 - 2025) Analysis & Trends
Precision Biosciences (DTIL) has 5 years of Equity Income data on file, last reported at -$2.9 million in Q4 2025.
- Equity Income for Q4 2025 came in at -$2.9 million, down 194.86% year-over-year; the trailing twelve-month figure through Mar 2026 was -$5.9 million (down 1831.29% YoY), and the FY2025 annual result was -$5.3 million, down 387.45% from the prior year.
- Equity Income eased to -$2.9 million in Q4 2025 per DTIL's latest filing, from -$591000.0 in the prior quarter.
- Over five years, Equity Income peaked at $5.2 million in Q4 2023 and troughed at -$2.9 million in Q4 2025.
- A 5-year average of -$29055.6 and a median of -$271000.0 in 2025 frame the typical range for Equity Income.
- On a YoY basis, Equity Income climbed as much as 1736.5% in 2022 and fell as far as 750.36% in 2022.
- A 5-year view of Equity Income shows it stood at $200000.0 in 2021, then jumped by 1736.5% to $3.7 million in 2022, then surged by 41.71% to $5.2 million in 2023, then sank by 118.67% to -$972000.0 in 2024, then slumped by 194.86% to -$2.9 million in 2025.
- Business Quant data shows DTIL's Equity Income at -$2.9 million in Q4 2025, -$591000.0 in Q3 2025, and -$2.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Precision Biosciences | 168.99 Mn | 67.81 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.87 Mn |
| Sep 30, 2025 | -591,000.00 |
| Jun 30, 2025 | -2.46 Mn |
| Mar 31, 2025 | 49,000.00 |
| Dec 31, 2024 | -972,000.00 |
| Sep 30, 2024 | 571,000.00 |
| Jun 30, 2024 | 694,000.00 |
| Mar 31, 2024 | 1.71 Mn |
| Dec 31, 2023 | 5.21 Mn |
| Sep 30, 2023 | 311,000.00 |
| Jun 30, 2023 | -1.37 Mn |
| Mar 31, 2023 | -769,000.00 |
| Dec 31, 2022 | 3.67 Mn |
| Sep 30, 2022 | -1.78 Mn |
| Jun 30, 2022 | -1.45 Mn |
| Mar 31, 2022 | -952,000.00 |
| Dec 31, 2021 | 200,000.00 |
| Sep 30, 2021 | 274,000.00 |